Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Urinary hydrocodone and metabolite distributions in pain patients.

Barakat NH, Atayee RS, Best BM, Ma JD.

J Anal Toxicol. 2014 Sep;38(7):404-9. doi: 10.1093/jat/bku051. Epub 2014 May 17.

PMID:
24836897
2.

Observations of urinary oxycodone and metabolite distributions in pain patients.

Elder NM, Atayee RS, Best BM, Ma JD.

J Anal Toxicol. 2014 Apr;38(3):129-34. doi: 10.1093/jat/bku007. Epub 2014 Feb 11.

PMID:
24523296
3.

Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: comparison with urine.

Cao JM, Ma JD, Morello CM, Atayee RS, Best BM.

J Opioid Manag. 2014 May-Jun;10(3):177-86. doi: 10.5055/jom.2014.0206.

PMID:
24944068
4.

Observations on the urine metabolic profile of codeine in pain patients.

Yee DA, Atayee RS, Best BM, Ma JD.

J Anal Toxicol. 2014 Mar;38(2):86-91. doi: 10.1093/jat/bkt101. Epub 2014 Jan 6.

PMID:
24396053
5.

Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers.

Valtier S, Bebarta VS.

J Anal Toxicol. 2012 Sep;36(7):507-14. doi: 10.1093/jat/bks058. Epub 2012 Jul 10.

PMID:
22782534
6.

CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA.

Br J Clin Pharmacol. 2004 Mar;57(3):287-97.

7.

Relationship between the concentration of hydrocodone and its conversion to hydromorphone in chronic pain patients using urinary excretion data.

Barakat NH, Atayee RS, Best BM, Pesce AJ.

J Anal Toxicol. 2012 May;36(4):257-64. doi: 10.1093/jat/bks019.

PMID:
22511700
8.

Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives.

Cone EJ, Zichterman A, Heltsley R, Black DL, Cawthon B, Robert T, Moser F, Caplan YH.

Forensic Sci Int. 2010 May 20;198(1-3):58-61. doi: 10.1016/j.forsciint.2009.12.005. Epub 2009 Dec 29.

PMID:
20036472
9.

The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone.

Boswell MV, Stauble ME, Loyd GE, Langman L, Ramey-Hartung B, Baumgartner RN, Tucker WW, Jortani SA.

Pain Physician. 2013 May-Jun;16(3):E227-35.

10.

In vivo activity of norhydrocodone: an active metabolite of hydrocodone.

Navani DM, Yoburn BC.

J Pharmacol Exp Ther. 2013 Nov;347(2):497-505. doi: 10.1124/jpet.113.207548. Epub 2013 Aug 30.

11.

Prescription opioids. II. Metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration.

Cone EJ, Heltsley R, Black DL, Mitchell JM, Lodico CP, Flegel RR.

J Anal Toxicol. 2013 Oct;37(8):486-94. doi: 10.1093/jat/bkt066. Epub 2013 Aug 14.

PMID:
23946451
12.

Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.

Kapil RP, Friedman K, Cipriano A, Michels G, Shet M, Mondal SA, Harris SC.

Clin Ther. 2015 Oct 1;37(10):2286-96. doi: 10.1016/j.clinthera.2015.08.007. Epub 2015 Sep 6. Erratum in: Clin Ther. 2016 Jan 1;38(1):232.

13.

Therapeutic monitoring of opioids: a sensitive LC-MS/MS method for quantitation of several opioids including hydrocodone and its metabolites.

Langman LJ, Korman E, Stauble ME, Boswell MV, Baumgartner RN, Jortani SA.

Ther Drug Monit. 2013 Jun;35(3):352-9. doi: 10.1097/FTD.0b013e318283e29a.

PMID:
23666565
14.

Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites.

Heltsley R, Zichterman A, Black DL, Cawthon B, Robert T, Moser F, Caplan YH, Cone EJ.

J Anal Toxicol. 2010 Jan-Feb;34(1):32-8.

PMID:
20109300
15.

Hydrocodone in postoperative personalized pain management: pro-drug or drug?

Stauble ME, Moore AW, Langman LJ, Boswell MV, Baumgartner R, McGee S, Metry J, Jortani SA.

Clin Chim Acta. 2014 Feb 15;429:26-9. doi: 10.1016/j.cca.2013.11.015. Epub 2013 Nov 21.

PMID:
24269714
16.

Variability in metabolism of imipramine and desipramine using urinary excretion data.

Ramey K, Ma JD, Best BM, Atayee RS, Morello CM.

J Anal Toxicol. 2014 Jul-Aug;38(6):368-74. doi: 10.1093/jat/bku034. Epub 2014 Apr 29.

PMID:
24782142
17.

Sensitivity of an opiate immunoassay for detecting hydrocodone and hydromorphone in urine from a clinical population: analysis of subthreshold results.

Bertholf RL, Johannsen LM, Reisfield GM.

J Anal Toxicol. 2015 Jan-Feb;39(1):24-8. doi: 10.1093/jat/bku109. Epub 2014 Oct 6.

PMID:
25288720
18.

[Studies on the analysis of hydrocodone and its metabolite in human urine by GC/MS].

Wu Y.

Yao Xue Xue Bao. 1997 Apr;32(4):305-9. Chinese.

PMID:
11499035
19.
20.

Breast milk hydrocodone and hydromorphone levels in mothers using hydrocodone for postpartum pain.

Sauberan JB, Anderson PO, Lane JR, Rafie S, Nguyen N, Rossi SS, Stellwagen LM.

Obstet Gynecol. 2011 Mar;117(3):611-7. doi: 10.1097/AOG.0b013e31820ca504.

PMID:
21343764

Supplemental Content

Support Center